ema semaglutide GLP-1 Drug Can Cause Rare, Potentially Blinding Side Effect, Warns EMA backs Novo's Wegovy pill,

Choosing an injection time that fits your schedule and body can make a meaningful difference in managing those effects, and in how easy it is to stick with your routine long-term

Research: The STEP trials assessed weight loss in people with obesity receiving a once-weekly injection of semaglutide (Wegovy) over 17 months (68 weeks)

For some patients, obesity pharmacotherapy may be a long-term treatment rather than a time-limited intervention

Research suggests it is less effective for weight loss, and it has never been approved for that purpose

Some aim to provide even greater weight loss than current options, while others are being studied for their potential to preserve muscle mass during weight lossa key factor for maintaining metabolic health and physical performance